1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
TNF Pharmaceuticals reports $2.50 loss per share for the quarter
TNF Pharmaceuticals on November 19, 2025 released results for the quarter ended September 30, 2025, reporting a loss per share of $2.50. In the year-ago quarter, a loss of -111,000 USD per share was reported. » More on finanzen.net
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -4.68K | - |
| Net profit | -5.8M | 280.41% |
| EBITDA | -3.16M | 107.57% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €3.61M |
Number of shares | 1.77M |
52-week high/low | €7.72 - €1.99 |
| Dividends | No |
Beta | 2.11 |
P/E ratio | -0.54 |
PEG ratio | 0.00 |
P/B ratio | 1.01 |
P/S ratio | 0.00 |
Company profile
| Name | TNF Pharmaceuticals |
| CEO | Joshua N. Silverman |
| Employees | 3 |
Discover assets
Shareholders of TNF Pharmaceuticals also invest in the following assets
